Sökning: "CYP2B6"
Visar resultat 1 - 5 av 17 avhandlingar innehållade ordet CYP2B6.
1. Regulation and polymorphism of CYP2A6, CYP2B6 and CYP2E1 : functional and clinical aspects
Sammanfattning : Cytochrome P450s constitute a superfamily of heme-binding monooxygenases that play important roles in the metabolism of endogenous substrates and a wide variety of exogenous substances, such as toxins and drugs, and participate as well in the biosynthesis of steroids, fatty acids, vitamins and bile acids. The P450s genes are subjects for large inter-individual variability in expression, which subsequently cause inter-individual differences in drug metabolism. LÄS MER
2. Pharmacogenetic and pharmacokinetic studies of cyclophosphamide : in cell, animal and human
Sammanfattning : Cyclophosphamide (CPA) is widely used anti-cancer drug that has to be catalyzed by the cytochrome P450 (CYP) enzyme 2B6 as well as some other CYPs to exert its cytotoxic activity. A high degree of interindividual variation in CPA kinetics has been reported in both children and adult patients, which may be due to several factors such as concomitantly used drugs, variation in physiological status of individual patients and genetic polymorphism of the CYP enzymes. LÄS MER
3. Pharmacogenetic aspects of HIV/AIDS, tuberculosis and malaria : emphasis on Ugandan population
Sammanfattning : Infectious diseases such as HIV, tuberculosis and malaria are endemic in Africa and often require concomitant treatments that may result into subsequent drug–drug interactions. Inter-individual variability in the pharmacokinetics and pharmacodynamics of drugs used in infectious diseases, as a result of genetic polymorphism, has been reported. LÄS MER
4. Pharmacokinetic and pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients : implication for optimization of TB-HIV co-treatment
Sammanfattning : TB and HIV are immuno-pathologically interacting epidemic infectious diseases affecting the lives of millions globally & sub-Saharan African region accounts the highest burden of both diseases. Although effective therapies are available for the management of each, TB-HIV co-treatment has faced challenges mainly due to drug-drug interactions & overlapping drug toxicities. LÄS MER
5. Optimization of HIV and tuberculosis co-treatment in Tanzanian patients : emphasis on pharmacogenetics and drug interactions
Sammanfattning : Treatment of HIV and its comorbidities particularly tuberculosis is complicated by wide inter-individual variations in drug exposure due to drug-interactions and variable expressions of drug metabolizing enzymes and transporters. Efavirenz in particular, is an antiretroviral characterized by wide inter-individual variation in exposure. LÄS MER
